6. Parkinson disease
2,123 clinical trials,   2,046 drugs   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04403399
(ClinicalTrials.gov)
June 29, 201721/5/2020Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Exp. 3 - Proj#3 (UdallP3)Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Exp. 3 - Proj#3Parkinson's DiseaseDrug: Varenicline;Other: Evaluation by Investigator;Other: PlaceboUniversity of MichiganNULLCompleted45 YearsN/AAll33Phase 2United States
2NCT02933372
(ClinicalTrials.gov)
October 5, 20156/4/2016Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Projects #3Parkinson's DiseaseDrug: Varenicline;Radiation: [18-Fluorine] Flubatine PET Scan;Other: Evaluation by InvestigatorUniversity of MichiganNULLCompleted45 YearsN/AAll25Phase 2NULL
3NCT02473562
(ClinicalTrials.gov)
May 201312/6/2015Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's DiseaseVarenicline, a Partial Nicotinic Receptor Agonist for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease: a Placebo-controlled Cross-over Pilot StudyParkinson's DiseaseDrug: Varenicline;Drug: Placebo (for varenicline)VU University Medical CenterCentre for Human Drug Research, NetherlandsTerminatedN/AN/AAll22Phase 4Netherlands
4EUCTR2012-001530-34-NL
(EUCTR)
09/08/201209/08/2012Vareniciline treatment for Excessive Daytime Sleepiness in Parkinson’s DiseaseVarenicline, a partial nicotinic receptor agonist for the treatment of Excessive Daytime Sleepiness in Parkinson’s Disease: a placebo-controlled cross-over study - Vareniciline for Excessive daytime Sleepiness in PArkinson’s disease (VESPA) Idiopathic Parkinson's disease
MedDRA version: 18.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Champix
INN or Proposed INN: VARENICLINE
Other descriptive name: VARENICLINE TARTRATE
VU University Medical CenterCenter Human Drug ResearchNot RecruitingFemale: yes
Male: yes
32Phase 3Netherlands
5NCT01341080
(ClinicalTrials.gov)
December 28, 201021/4/2011Varenicline for Gait and Balance Impairment in Parkinson DiseaseVarenicline for the Treatment of Postural and Gait Dysfunction in Parkinson DiseaseParkinson DiseaseDrug: Varenicline;Drug: Sugar pillRush University Medical CenterNULLCompleted40 Years90 YearsAll40Phase 2United States